Synact Pharma intensifies partnership discussions

Fresh off receiving positive results from a phase IIa study with arthritis candidate AP1189, biotech firm Synact Pharma prepares to look into partnership options.
Photo: Synact Pharma / PR
Photo: Synact Pharma / PR
by christopher due karlsson, translated by daniel pedersen

Synact Pharma is going in with good cards in a hunt for potential partners. Last week, the biotech firm could reveal promising results from a smaller phase IIa study with its drug candidate, AP1189, against arthritis.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading